 NEW YORK, Oct. 11, 2021 PRNewswire -- Rowley Law PLLC is investigating potential securities law violations by Flexion Therapeutics, Inc. NASDAQ: FLXN and its board of directors concerning the proposed acquisition of the company by Pacira BioSciences, Inc. NASDAQ: PCRX. Stockholders will receive 8.50 and one contingent value right worth up to 8.00 for each share of Flexion Therapeutics stock that they hold. 